Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.
We analysed measles antibody data from 1141 vaccinated Canadian children aged 4-16 years to investigate factors associated with seropositivity and magnitude of prevailing antibody titres. We used a mixed Bernoulli/log-gamma model which takes account of the possibility of primary vaccine failures, of censored observations due to the lower detection limit of antibody assays and of a potentially skewed distribution of the logarithm of titres. While controlling for all significant variables, we observed that measles antibody titres decline at a mean rate of 5.6% per annum (approximate 95% CI; 3.3-7.7) equivalent to a half life of 12 years. Further, we noted a detectable linear relationship with respect to age at immunisation such that the mean increase in measles antibody titre of an infant who responds to vaccination gained by delaying vaccination from 12 to 18 months of age is 11.1% (approximate 95% CI; 4.4-18.3).
Mossong
J
J
Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK. joel.mossong@crp-sante.lu
O'Callaghan
C J
CJ
Ratnam
S
S
D000293:Adolescent; D000367:Age Factors; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D016013:Likelihood Functions; D008297:Male; D008457:Measles / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D008954:Models, Biological
D000914:Antibodies, Viral; D008458:Measles Vaccine